Amanda Gordon

1.2k total citations
15 papers, 801 citations indexed

About

Amanda Gordon is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Amanda Gordon has authored 15 papers receiving a total of 801 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 5 papers in Genetics. Recurrent topics in Amanda Gordon's work include Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and CAR-T cell therapy research (4 papers). Amanda Gordon is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and CAR-T cell therapy research (4 papers). Amanda Gordon collaborates with scholars based in United States, Netherlands and Germany. Amanda Gordon's co-authors include Gordon C. Jayson, Hani Gabra, David E. Parkin, R. Atkinson, Stuart Kaye, A. Hay, Robert L. Coleman, P. Vasey, J. P. Paul and Christopher Turner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Amanda Gordon

15 papers receiving 779 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amanda Gordon United States 7 400 314 253 191 137 15 801
Joan Sorich United States 13 251 0.6× 439 1.4× 203 0.8× 330 1.7× 61 0.4× 31 759
Jim Biagi Canada 10 275 0.7× 158 0.5× 103 0.4× 238 1.2× 252 1.8× 17 648
Saverio Danese Italy 16 266 0.7× 408 1.3× 213 0.8× 228 1.2× 102 0.7× 31 880
M.L. Rothenberg United States 9 214 0.5× 363 1.2× 96 0.4× 368 1.9× 41 0.3× 14 781
L. Kayitalire France 17 158 0.4× 745 2.4× 173 0.7× 163 0.9× 67 0.5× 40 1.1k
Katarína Macháleková Slovakia 15 96 0.2× 264 0.8× 283 1.1× 187 1.0× 32 0.2× 47 684
Sally A. Mullany United States 15 221 0.6× 245 0.8× 282 1.1× 381 2.0× 134 1.0× 22 899
Corrine Zarwan United States 13 203 0.5× 691 2.2× 123 0.5× 321 1.7× 26 0.2× 27 1.1k
Malti Kshirsagar United States 9 125 0.3× 218 0.7× 94 0.4× 201 1.1× 90 0.7× 9 603
Keiji Kato Japan 17 117 0.3× 229 0.7× 279 1.1× 352 1.8× 129 0.9× 46 988

Countries citing papers authored by Amanda Gordon

Since Specialization
Citations

This map shows the geographic impact of Amanda Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Gordon more than expected).

Fields of papers citing papers by Amanda Gordon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Gordon. The network helps show where Amanda Gordon may publish in the future.

Co-authorship network of co-authors of Amanda Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda Gordon. A scholar is included among the top collaborators of Amanda Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda Gordon. Amanda Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Karschnia, Philipp, Sylvia C. Kurz, Priscilla K. Brastianos, et al.. (2023). Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens. Neurology. 101(17). e1741–e1746. 6 indexed citations
2.
Dietrich, Jörg, Jan Drappatz, April F. Eichler, et al.. (2020). Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. The Oncologist. 25(9). 747–e1273. 12 indexed citations
3.
Ahmadi, Tahamtan, Elise A. Chong, Amanda Gordon, et al.. (2013). Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas. Cancer. 120(2). 222–228. 36 indexed citations
4.
Chong, Elise A., Tahamtan Ahmadi, Nicole A. Aqui, et al.. (2013). High Response Rate To Combination Lenalidomide-Rituximab In FcγRIIIa-F Carriers With Indolent Or Mantle Cell Lymphomas Previously Refractory To Rituximab. Blood. 122(21). 250–250. 1 indexed citations
5.
Schuster, Stephen J., Chitra Hosing, Elizabeth J. Shpall, et al.. (2011). Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia. Blood. 118(21). 2855–2855. 1 indexed citations
6.
Schuster, Stephen J., Chitra Hosing, Elizabeth J. Shpall, et al.. (2011). Adoptive immunotherapy with autologous CD3/CD28-costimulated T cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia.. Journal of Clinical Oncology. 29(15_suppl). 2557–2557. 1 indexed citations
7.
Ahmadi, Tahamtan, Elise A. Chong, Amanda Gordon, et al.. (2011). Phase II Trial of Lenalidomide - Rituximab +/− Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab. Blood. 118(21). 266–266. 2 indexed citations
8.
Aqui, Nicole A., Leah I. Leinbach, Elise A. Chong, et al.. (2010). Changes in regulatory T-cells in responding and non-responding patients with indolent B-cell or mantle cell lymphomas during treatment with lenalidomide, dexamethasone, and rituximab.. Journal of Clinical Oncology. 28(15_suppl). 8085–8085. 1 indexed citations
9.
Ahmadi, Tahamtan, Elise A. Chong, Amanda Gordon, et al.. (2010). Phase II Trial of Lenalidomide - Dexamethasone - Rituximab In Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab. Blood. 116(21). 3962–3962. 9 indexed citations
10.
Manley, Peter, Xiaochun Li, Christopher D. Turner, et al.. (2009). A prospective, blinded analysis of A‐PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. Pediatric Blood & Cancer. 53(3). 343–347. 2 indexed citations
11.
Braly, Patricia S., Christina Chu, Robert P. Edwards, et al.. (2007). Prospective evaluation of front-line chemo-immunotherapy (C-IT) with oregovomab (2 alternative dosing schedules) carboplatin-paclitaxel (C-P) in advanced ovarian cancer (OC). Journal of Clinical Oncology. 25(18_suppl). 3024–3024. 5 indexed citations
12.
Kieran, Mark W., Christopher Turner, Joshua B. Rubin, et al.. (2005). A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer. Journal of Pediatric Hematology/Oncology. 27(11). 573–581. 155 indexed citations
13.
Jayson, Gordon C., Amanda Gordon, Hani Gabra, et al.. (2004). On behalf of the Scottish Gynaecological Cancer Trials Group. Phase III Randomized Trial of Docetaxel?Carboplatin Versus Paclitaxel?Carboplatin as First-line Chemotherapy for Ovarian Carcinoma. JNCI Journal of the National Cancer Institute. 1682–1691. 100 indexed citations
14.
Vasey, P., Gordon C. Jayson, Amanda Gordon, et al.. (2004). Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma. JNCI Journal of the National Cancer Institute. 96(22). 1682–1691. 446 indexed citations
15.
Huinink, W ten Bokkel, et al.. (1997). Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.. PubMed. 24(1 Suppl 5). S5–19. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joan Sorich Breakdown of academic impact, for papers by Jim Biagi Breakdown of academic impact, for papers by Saverio Danese Breakdown of academic impact, for papers by M.L. Rothenberg Breakdown of academic impact, for papers by L. Kayitalire Breakdown of academic impact, for papers by Katarína Macháleková Breakdown of academic impact, for papers by Sally A. Mullany Breakdown of academic impact, for papers by Corrine Zarwan Breakdown of academic impact, for papers by Malti Kshirsagar Breakdown of academic impact, for papers by Keiji Kato
Rankless by CCL
2026